A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

Research highlights media misrepresentation of COVID-19 drug efficacy. ... For the study, the researchers conducted an analysis of 479 reports of hydroxychloroquine, ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

FDA recognizes uncertainty in COVID-19 booster efficacy; ... commends new U.S. Food and Drug ... of RT-PCR-confirmed symptomatic COVID-19. The latest analysis from the Phase 3 ...

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier ...

To further improve the drug-like features of WYS-633, also with an eye towards oral bioavailability, the team performed another round of medical chemistry, AI-enabled computational analysis, and in ...